Ringelhan Marc, Protzer Ulrike
Institute of Virology, Technical University of Munich/Helmholtz Zentrum München, Munich, Germany; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany; Second Medical Department, University Hospital rechts der Isar, Technical University of Munich, Munich, Germany.
Institute of Virology, Technical University of Munich/Helmholtz Zentrum München, Munich, Germany; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany.
Curr Opin Virol. 2015 Oct;14:109-15. doi: 10.1016/j.coviro.2015.08.015. Epub 2015 Sep 29.
Due to the limited treatment options hepatocellular carcinoma (HCC) is one of the leading causes of cancer related death, and hepatitis B virus (HBV) infection is the major risk factor for development of HCC worldwide. HCC is typically preceded by chronic inflammation, but may also develop in the absence of liver disease on the basis of HBV infection and even when virus replication is controlled by antivirals. In this situation, HBV antigen expression persists and direct oncogenic effects of HBV are integration of the viral DNA into the host genome as well as direct effects of viral proteins. These factors have to be taken into account in order to personalize HCC surveillance in CHB and unravel novel therapeutic approaches.
由于治疗选择有限，肝细胞癌（HCC）是癌症相关死亡的主要原因之一，而乙型肝炎病毒（HBV）感染是全球HCC发生的主要危险因素。HCC通常先于慢性炎症出现，但也可能在没有肝脏疾病的情况下基于HBV感染而发生，甚至在病毒复制被抗病毒药物控制时也会发生。在这种情况下，HBV抗原表达持续存在，HBV的直接致癌作用包括病毒DNA整合到宿主基因组以及病毒蛋白的直接作用。为了实现慢性乙型肝炎（CHB）患者HCC监测的个性化并探索新的治疗方法，必须考虑这些因素。
